ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions
  • Abstract Number: 0141

    Cytokine profiles in antiphospholipid syndrome
  • Abstract Number: 0142

    Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
  • Abstract Number: 0143

    High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome
  • Abstract Number: 0144

    Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
  • Abstract Number: 0145

    Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
  • Abstract Number: 0146

    Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases
  • Abstract Number: 0147

    Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
  • Abstract Number: 0148

    Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
  • Abstract Number: 0149

    Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
  • Abstract Number: 0150

    Mortality in Anca-associated Vasculitis
  • Abstract Number: 0151

    Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
  • Abstract Number: 0152

    Exploring internet use and health information behaviour in patients with inflammatory rheumatic musculoskeletal diseases (RMD)
  • Abstract Number: 0153

    Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
  • Abstract Number: 0154

    Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
  • Abstract Number: 0155

    Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology